In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Genetic disruption of multidrug resistance-associated protein 1 improves endothelial function and attenuates atherosclerosis in MRP1-/- LDL-/- double knockout mice.

Session The immune system in cardiovascular disease

Speaker Julian Jehle

Event : ESC Congress 2016

  • Topic : basic science
  • Sub-topic : Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis
  • Session type : Moderated Posters

Authors : J Jehle (Bonn,DE), CFH Mueller (Bonn,DE), A Aksoy (Bonn,DE), S Zimmer (Bonn,DE), G Nickenig (Bonn,DE), V Tiyerili (Bonn,DE)

Authors:
J. Jehle1 , C.F.H. Mueller1 , A. Aksoy1 , S. Zimmer1 , G. Nickenig1 , V. Tiyerili1 , 1University Hospital Bonn, Department of Cardiology - Bonn - Germany ,

Citation:
European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 1009

Background: Multidrug resistance-associated protein 1 (MRP1) is an anion transporter which is implicated in the efflux of the intracellular antioxidant anion glutathione as well as leukotrienes. Pharmacological inhibition of MRP1 exhibits antioxidative and antiatherosclerotic effects both in vitro and in vivo. However, pharmacological inhibitors of MRP1 lack selectivity which prompted us to study the in vivo impact of a genetic disruption of MRP1 on endothelial dysfunction, reactive oxygen species formation and atherogenesis in an atherosclerotic mouse model.

Methods: We crossed atherosclerosis-prone LDL–/– mice and MRP1–/– mice of FVB origin to generate MRP1–/– LDL–/– double knockout mice. These mice were fed a high-fat and cholesterol-rich diet for 7 weeks. Hereafter, endothelial function was assessed in isolated aortic rings. Reactive oxygen species were quantified by L-012 chemiluminescence and the atherosclerotic plaque burden was measured following oil red O staining.

Results: Endothelium-dependent vasodilation of MRP1–/– LDL–/– double knockout mice was significantly improved compared to MRP1-competent LDL–/– single knockout mice. This improvement was accompanied by a significant reduction in reactive oxygen species formation within the aortic tissue. Moreover, the atherosclerotic plaque burden of MRP1–/– LDL–/– double knockout mice was significantly reduced. Finally, arterial blood pressure was significantly reduced in MRP1–/– LDL–/– double knockout mice.

Conclusion: Genetic disruption of MRP1 appears to reduce blood pressure and vascular oxidative stress in vivo, which leads to an improved endothelial function and a reduced plaque burden in atherosclerotic mice. Therefore, MRP1 might represent a promising therapeutic target to improve endothelial function in patients suffering from atherosclerosis.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are